Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for the three months ended March 31, 2026.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for the three months ended March 31, 2026
- Press release issued May 5, 2026, with full financial details in Exhibit 99.1
- Investor focus: quarterly performance, liquidity, and pipeline updates in the furnished release
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $128M, or $1.02 per share, versus $112M and $1.14 in Q1 2025
- Cash, equivalents and marketable securities fell to $876M from $1.01B, with runway projected through at least the second half of 2028
- Casdatifan PEAK-1 enrollment targeted for completion by year-end 2026, alongside planned initiation of a first-line Phase 3 study
- Casdatifan plus zimberelimab showed 7% primary progression in 2L? No, 1L ARC-20 cohort, supporting potential TKI-free first-line positioning
- Domvanalimab STAR-121 and EDGE-Lung discontinued after futility analysis showed no OS improvement versus pembrolizumab plus chemotherapy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.